Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Rg1-preconditioned adipose-derived mesenchymal stromal cells alleviate colitis via exosome-mediated Inhibition of macrophage glycolysis through RAS signaling.

Fang Y., Chen Y., Yu X., Zhang J., Zhu W., Mou C.

Animal Study on Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41316493
PMCID
PMC12870250
DOI
10.1186/s13287-025-04822-4
Citations
2

Abstract (original English)

Aims The therapeutic potential of adipose-derived mesenchymal stromal cells (ADSCs) in inflammatory bowel disease (IBD) is well established, yet the mechanisms underlying their immunoregulatory effects remain unclear. Ginsenoside Rg1 has been shown to enhance the immunomodulatory properties of ADSCs. Given the key role of macrophages in IBD pathogenesis, this study aimed to explore whether mesenchymal stromal cells (MSCs), particularly following Rg1 pretreatment, alleviate colitis by modulating macrophage immunometabolism. Main methods In vitro experiments were performed in RAW264.7 macrophages and NCM460 cell. In vivo experiments were performed in C57BL/6 mice. Key findings Rg1 pretreatment upregulated stemness-related genes and downregulated immunogenic markers in ADSCs. In vivo, Rg1-preconditioned ADSCs significantly alleviated DSS-induced colitis and inhibited M1 macrophage polarization by reducing glycolytic activity. Mechanistically, ADSC-derived exosomes delivered miRNAs that suppressed glycolysis and RAS signaling in macrophages, thereby limiting pro-inflammatory polarization and ameliorating colitis. This miRNA is presumed to be miR-574-3p. Significance MSCs alleviate experimental colitis by modulating macrophage immunometabolism, and Rg1 pretreatment further enhances this therapeutic potential. This effect may involve exosomal miRNAs that inhibit macrophage glycolysis

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsMiceMacrophagesExosomesColitisGinsenosidesMice, Inbred C57BLGlycolysisSignal Transduction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research